Connecta Therapeutics
Phase 1At CONNECTA, we are driven to make innovative treatments available to patients suffering from CNS disorders. We strongly believe we can succeed in meaningfully improving the lives of patients and their families.
Founded
2019
Focus
Small Molecules
About
At CONNECTA, we are driven to make innovative treatments available to patients suffering from CNS disorders. We strongly believe we can succeed in meaningfully improving the lives of patients and their families.
Pipeline Snapshot
11 drug in pipeline
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| CTH120 | Fragile X Syndrome | Phase 1 |
Funding History
2Total raised: $2.5M
Seed$2MUndisclosedNov 15, 2022
Grant$500KSpanish Ministry of ScienceMar 15, 2021
Company Info
TypePrivate
Founded2019
LocationBarcelona, Spain
StagePhase 1
Contact
SIMILAR COMPANIES
A4Cell
Pre-clinical · Barcelona
Ability Pharma
Phase 2 · Barcelona
Abyntek Biopharma
Pre-clinical · Derio
Acellera
Pre-clinical · Barcelona
BeCytes Biotechnologies
Pre-clinical · Barcelona
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile